Sun Pharma, Dr. Reddy’s, Aurobindo recall products in the US market

Sun Pharma, Dr. Reddy’s, Aurobindo recall products in the US market

Dr. 2,24,710 (500 count) bottles of atorvastatin calcium tablets are being recalled in Reddy’s laboratories.

The leading domestic pharmaceutical manufacturer Sun Pharma, Drs. Reddy’s Laboratories, Aurobindo Pharma and Jubilant Pharma are recalling the world’s largest market for pharmaceutical products in the US market for various reasons.

According to the latest enforcement report by the US Food and Drug Administration (USFDA), Sun Pharma is recalling the Cequa ophthalmic solution, which is used to treat chronic dry eyes.

The US health regulator said the Mumbai-based drug subsidiary is recalling 37,400 cartons (60 cartons per carton (60 vials per carton) as an athalmic solution.

The Princeton (NJ) based firm took a nationwide recall of the affected lots on February 22 of this year.

Likewise, Drs. Reddy’s Laboratories is recalling 10,440 (90-count) and 2,24,710 (500-count) atorvastatin calcium tablets in the US market.

The USFDA said the Hyderabad-based firm is withdrawing the drug, which is used to prevent heart disease.

The US-based unit of the drug major initiated a nationwide recall on February 19, 2021, and the USFDA has classified it as a Class III recall, in a “situation in which use, or not to a violent product, occurs.” Has been initiated. ” Adverse health consequences are likely ”.

The pharmaceutical company is also recalling 16,449 bottles of progesterone capsules (200 mg), which are used for menstrual periods in women who have not yet reached menopause in the US market for “failed dissolution specifications”.

The company took a nationwide recall initiative on February 26 this year, and the USFDA classified it as a second-class recall, which is initiated in a situation in which someone’s use, or exposure to it , A violent product may be temporary or medically reversible adverse health consequences or where the likelihood of serious adverse health consequences is remote.

Another Hyderabad-based drug major Aurobindo Pharma is reminding 1,296 bottles of femotidine tablets used to treat gastroesophageal reflux disease in the US market for the presence of foreign pills.

The USFT said, “Femotidine 20mg and ibuprofen 400mg pills were found in a lot of famotidine 40mg.”

The company began a nationwide recall on January 20 and the USFDA has classified the action as a second-tier.

In addition, Salisbury-based Jubilant Cadista Pharmaceuticals is recalling 6,35,400 cartons of methylprednisolone tablets due to its “illegal label” in the US market for its anti-inflammatory and anti-inflammatory effects.

The USFDA stated, “Customer complaint received regarding misalignment print of dosage instructions printed on blister card.”

The company began a nationwide recall on 19 February and the USFDA has classified the action as a Class III recall.

Jubilant Cadista Pharmaceuticals is a subsidiary of Singapore-based Jubilant Pharma, which in turn is a wholly owned subsidiary of Noida-based Jubilant Life Sciences.

You have reached your limit for free articles this month.

Membership benefits included

Today’s paper

Get a mobile-friendly version of the article from the newspaper of the day in an easy-to-read list.

unlimited access

Enjoy reading as many articles as you want without any limitations.

Personal recommendations

A selected list of articles that match your interests and tastes.

Fast page

Move seamlessly between articles as our pages load instantly

Dashboard

One-stop-shop to see the latest updates and manage your preferences.

Talk

We inform you about the latest and most important events three times a day.

Support quality journalism.

* Our digital subscription plans currently do not include e-paper, crosswords and print.

.

Be the first to comment

Leave a Reply

Your email address will not be published.


*